Friday, July 08, 2005

Astragalus (Astragalus membranaceus)

Astragalus (Astragalus membranaceus)


Background


Astragalus products are derived from the roots of Astragalus membranaceus or related species, which are native to China. In traditional Chinese medicine, astragalus is commonly found in mixtures with other herbs, and is used in the treatment of numerous ailments, including heart, liver, and kidney diseases, as well as cancer, viral infections, and immune system disorders. Western herbalists began using astragalus in the 1800s as an ingredient in various tonics. The use of astragalus became popular in the 1980s based on theories about anti-cancer properties, although these proposed effects have not been clearly demonstrated in reliable human studies.

Some medicinal uses of astragalus are based on its proposed immune stimulatory properties, reported in preliminary laboratory and animal experiments, but not conclusively demonstrated in humans. Most astragalus research has been conducted in China, and has not been well designed or reported.

Gummy sap (tragacanth) from astragalus is used as a thickener (ice cream), emulsifier, denture adhesive, and anti-diarrheal agent.

Synonyms


Astragalus trigonus, Astragalus gummifera, Astragalus mollissimus, Astragalus lentiginosus , astragel, baak kei, beg kei, bei qi, buck qi, Fabacea (family) , goat's horn, goat's thorn, green dragon, gum dragon, gum tragacanthae, gummi tragacanthae, hoang ky, hog gum, huang-chi, Huang Qi, huangoi, huangqi, hwanggi, ji cao, Leguminosae (family), locoweed, membranous milk vetch, milk vetch, mongolian milk, mongolian milk vetch, neimeng hhuangqi, ogi, ougi, radix astragali, spino santo, Syrian tragacanth, tai shen, tragacanth, wong kei, yellow vetch, Zhongfengnaomitong.

Selected combination products that include this agent : Astragalus-Power, Baoyuan Dahuang, Biomune OSF Plus, Bu Zhong Yi Qi Tang, CH-100, Chi Power, Chinese Thermo-Chi, Deep Defense, Energy Boost Tincture, Equi-lizer Fast Start, Excel Energy, Fast Start, Fit America Natural Weight Control Aid, Formula One, Formula 3, Formula 3 Cell Activator, Fu-Zheng, Han-Dan-Gan-Le, Herbal Balance, Intra, Jian Yan Ling (JYL), Jiangtangjia, Magic Herb Diet Plus Formula + Chromium Picolinate, Man-Shen-Ling (MSL), Master Herb with Chromium Picolinate, Megawatt, Nature's Nutrition Formula One, Nature's Power Trim Super Fat Burner, New Image, New Image Plus, Sanhuang, Shengxue Mixture (SXM), Shen-Qi, Shi-quan-da-bu-tang (SQT), Thermojetics Beige, Tri-Chromaleane, Ultra Energy Now, Vita Chromaleane, Yi-qi Huo-xue injection (YHI), Yogi Herbal Tea.

Evidence

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Uses based on scientific evidenceGrade*Cancer
Although early laboratory and animal studies report increased immune cell function and reduced cancer cell growth associated with the use of astragalus, there is no reliable human evidence in these areas. Due to a lack of well-designed research, a firm conclusion cannot be drawn.

C
Chemotherapy side effects
In Chinese medicine, astragalus-containing herbal mixtures are sometimes used with the intention to reduce side effects of cancer treatments. Due to a lack of well-designed research, a firm conclusion cannot be drawn.
C
Low white blood cell count
Astragalus has been suggested as an immune system stimulant in preliminary laboratory and animal research, and in traditional accounts. There are published reports from China of white blood cell counts increasing during the use of astragalus preparations, although details are limited. Reliable scientific study has not been conducted in this area. High quality human research is necessary before a firm conclusion can be drawn.
C
Immune stimulation
Astragalus has been suggested as an immune system stimulant in preliminary laboratory and animal research, and in traditional accounts. Reliable human studies are lacking. High quality human research is necessary before a firm conclusion can be drawn.
C
Anti-viral activity
Anti-viral activity has been reported with the use of astragalus in laboratory and animal studies. Limited human research has examined the use of astragalus for viral infections in the lung, heart (pericarditis), liver (hepatitis B and C), cervix (papilloma virus), and in HIV disease. Studies have included combinations of astragalus with the drug interferon, or as a part of herbal mixtures. However, most studies have been small and poorly designed. Due to a lack of well-designed research, no firm conclusions can be drawn.
C
Upper respiratory tract infection
Astragalus is often used in Chinese medicine as a part of herbal mixtures to prevent or treat upper respiratory tract infections. Anti-viral activity has been reported in laboratory and animal studies, and in limited human reports. However, most studies have been small and poorly designed. Due to a lack of well-designed research, no firm conclusions can be drawn.
C
Coronary artery disease
In Chinese medicine, herbal mixtures containing astragalus have been used to treat heart diseases. There are several human case reports of reduced symptoms and improved heart function, although these are not well described. High quality human research is necessary before a conclusion can be drawn.
C
Heart failure
In Chinese medicine, herbal mixtures containing astragalus have been used to treat various heart diseases. There are several human case reports of reduced symptoms and improved heart function, and diuretic ("water pill") effects, although these are not well described. High quality human research is necessary before a conclusion can be drawn.
C
Myocarditis/endocarditis (heart infections)
Anti-viral activity has been reported in laboratory studies and animal models of myocarditis/endocarditis. Human research is limited in this area, and further research is necessary before a conclusion can be drawn.
C
Renal failure
Several animal and human studies report that kidney damage from toxins and kidney failure may be improved with the use of astragalus-containing herbal mixtures. Overall, this research has been poorly designed and reported. Astragalus alone has not been well evaluated. Better quality research is necessary before a conclusion can be drawn.
C
Liver protection
Several animal and human studies report that astragalus may protect the liver from damage related to toxins or hepatitis B and C. Overall, this research has been poorly designed and reported. Astragalus alone has not been well evaluated. Better quality research is necessary before a conclusion can be drawn.
C
ya you betcha
* Key to grades
A: Strong scientific evidence for this use;
B: Good scientific evidence for this use;
C: Unclear scientific evidence for this use;
D: Fair scientific evidence against this use (it may not work);
F: Strong scientific evidence against this use (it likely does not work).


Uses based on tradition or theory
The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Adrenal insufficiency (Addison's disease), aging, AIDS/HIV, allergies, Alzheimer's disease, anemia, angina, ankylosing spondylitis, anorexia, antifungal, antimicrobial, antioxidant, asthma, blood thinner, bone-marrow suppression from cancer or HIV, bronchitis, cervicitis, "chi deficiency" (fatigue, weakness, loss of appetite), chronic fatigue syndrome, chronic hepatitis, cleanser, cyclosporine-induced immune suppression, dementia, demulcent, denture adhesive (astragalus sap), diabetes, diabetic foot ulcers, diabetic neuropathy, diarrhea, digestion enhancement, diuretic (urination stimulant), edema, fatigue, fever, gangrene, gastrointestinal disorders, genital herpes, graft-versus-host disease, hearing damage from toxins/gentamicin, heart attack, hemorrhage (bleeding), hemorrhoids, high cholesterol, high blood pressure, hyperthyroid, insomnia, joint pain, laxative, leprosy, leukemia, liver disease, low blood platelets, lung cancer, memory, menstrual disorders, metabolic disorders, minimal brain dysfunction, myalgia (muscle pain), myasthenia gravis, nephritis, night sweats, palpitations, pelvic congestion syndrome, postpartum fever, postpartum urinary retention, prostatitis, rectal prolapse, rotovirus enterocolitis (infants), shortness of breath, sperm motility, stamina/endurance enhancement, stomach ulcer, stroke, sweating (excessive), systemic lupus erythematosus (SLE), tissue oxygenation, uterine prolapse, uterine bleeding, weight loss, wound healing.

Dosing

The below doses are based on scientific research, publications, traditional use, or expert opinion. Many herbs and supplements have not been thoroughly tested, and safety and effectiveness may not be proven. Brands may be made differently, with variable ingredients, even within the same brand. The below doses may not apply to all products. You should read product labels, and discuss doses with a qualified healthcare provider before starting therapy.

Standardization

Standardization involves measuring the amount of certain chemicals in products to try to make different preparations similar to each other. It is not always known if the chemicals being measured are the "active" ingredients. Anecdotal reports have recommended astragalus to be standardized to a minimum of 0.4% 4-hydroxy-3-methoxy-isoflavone-7-glycoside per dose. However, since astragalus is often added to herbal mixtures with unclear amounts used, standardization is not always possible.

Adults (18 years and older)

General use by mouth : In Chinese medicine, astragalus is used in soups, teas, extracts, and pill form. In practice and in most scientific studies, astragalus is one component of multi-herb mixtures. Therefore, precise dosing of astragalus alone is not clear. Safety and effectiveness are not clearly established for any particular dose. Various doses of astragalus have been used or studied, including 250 to 500 milligrams of extract taken 4 times daily; 1 to 30 grams of dried root taken daily (doses as high as 60 grams have been reported); or 500 to 1000 milligrams of root capsules taken 3 times daily. Dosing of tinctures or fluid extracts depends on strength of preparations.

Note : In theory, consumption of the tragacanth (gummy sap derived from astragalus) may reduce absorption of drugs taken by mouth, and should be taken at separate times.

Children (younger than 18 years)

There is not enough scientific data to recommend astragalus for use in children.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Allergies

In theory, patients with allergies to members of the Leguminosae (pea) family may react to astragalus. Cross-reactivity with quillaja bark (soapbark) has been reported for astragalus gum tragacanth.

Side Effects and Warnings

Some species of astragalus have caused poisoning in livestock, although these types are usually not used in human preparations (which primarily include Astragalus membranaceus ). Livestock toxicity, referred to as "locoweed" poisoning, has occurred with species that contain swainsonine ( Astragalus lentiginosus, Astragalus mollissimus, Astragalus nothrosys, Astragalus pubentissimus, Astragalus thuseri, Astragalus wootoni ), or in species that accumulate selenium ( Astragalus bisulcatus, Astragalus flavus, Astragalus praelongus, Astragalus saurinus, Astragalus tenellus ).

Overall, it is difficult to determine the side effects or toxicity of astragalus, because it is most commonly used in combination with other herbs. There are numerous reports of side effects ranging from mild to deadly in the United States Food and Drug Administration computer database, although most of these are with multi-ingredient products, and cannot be attributed to astragalus specifically. Astragalus used alone and in recommended doses is traditionally considered to be safe, although safety is not well studied. The most common side effects appear to be mild stomach upset and allergic reactions. In the United States, tragacanth (astragalus gummy sap) has been classified as GRAS (generally recognized as safe) for food use, but astragalus does not have GRAS status.

Based on preliminary animal studies and limited human research, astragalus may decrease blood sugar levels. Caution is advised in patients with diabetes or hypoglycemia, and in those taking drugs, herbs, or supplements that affect blood sugar. Serum glucose levels may need to be monitored by a healthcare professional, and medication adjustments may be necessary.

Based on anecdotal reports and preliminary laboratory research, astragalus may increase the risk of bleeding. Caution is advised in patients with bleeding disorders or taking drugs that may increase the risk of bleeding. Dosing adjustments may be necessary.

Preliminary reports of human use in China have noted decreased blood pressure at doses below 15 grams and increased blood pressure at doses above 30 grams. Animal research suggests possible blood pressure lowering effects. Due to a lack of well-designed studies, no firm conclusions can be drawn. Nonetheless, people with abnormal blood pressure or taking blood pressure medications should use caution and be monitored by a qualified healthcare professional. Palpitations have been noted in human reports in China.

Based on animal study, astragalus may act as a diuretic and increase urination. In theory, this may lead to dehydration or metabolic abnormalities. There is one report of pneumonia in an infant after breathing in an herbal medicine powder including Astragalus sarcocolla .

Astragalus may increase growth hormone levels.

Pregnancy and Breastfeeding

There is not enough scientific evidence to recommend the safe use of Astragalus membranaceus during pregnancy or breastfeeding. Studies of toxic astragalus species, such as Astragalus lentiginosus or Astragalus mollissimus (locoweed) have reported harmful effects during animal pregnancies, leading to abortions or abnormal heart development.

References

Al-Fakhri SA. Herbal medicine: possible cause of aspiration pneumonia: A case report. Saudi Pharm J 1998;6(1):88-91.
Batey RG, Bensoussan A, Fan YY, et al. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998;13(3):244-247.
Bedir E, Pugh N, Calis I, et al. Immunostimulatory effects of cycloartane-type triterpene glycosides from astragalus species. Biol Pharm Bull 2000;23(7):834-837.
Bisignano G, Iauk L, Kirjavainen S, et al. Anti-inflammatory, analgesic, antipyretic and antibacterial activity of Astragalus siculus biv. Int J Pharm 1994;32(4):400-405.
Burack JH, Cohen MR, Hahn JA, et al. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(4):386-393.
Chen KT, Su CH, Hsin LH, Su YC, Su YP, Lin JG. Reducing fatigue of athletes following oral administration of huangqi jianzhong tang. Acta Pharmacol Sin. 2002 Aug;23(8):757-61.
Chen LX, Liao JZ, Guo WQ. [Effects of Astragalus membranaceus on left ventricular function and oxygen free radical in acute myocardial infarction patients and mechanism of its cardiotonic action]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(3):141-143.
Chu DT, Lepe-Zuniga J, Wong WL, et al. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol 1988;26(4):183-187.
Chu DT, Lin JR, Wong W. [The in vitro potentiation of LAK cell cytotoxicity in cancer and AIDS patients induced by F3--a fractionated extract of Astragalus membranaceus]. Zhonghua Zhong.Liu Za Zhi. 1994;16(3):167-171.
Chu DT, Sun Y, Lin JR. [Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients in vitro and reversal of cyclophosphamide-induced immune suppression in the rat in vivo by fractionated Astragalus membranaceus]. Zhong Xi Yi Jie He Za Zhi 1989;9(6):351-4, 326.
Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 1988;25(3):125-129.
Coppes MJ, Anderson RA, Egeler RM, et al. Alternative therapies for the treatment of childhood cancer. N Engl J Med 1998;339 (12) :846-847.
Cuellar M, Giner RM, Recio MC, et al. Screening of antiinflammatory medicinal plants used in traditional medicine against skin diseases. Phytother Res 1998;12:18-23.
Cui R, He J, Wang B, Zhang F, Chen G, Yin S, Shen H. Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother Pharmacol. 2003 Jan;51(1):75-80. Epub 2002 Nov 26.
Dai CF, Zhang ZZ, Qi XL, Zhang MX, Li YP. [Clinical and experimental study of treatment of nanmiqing capsule for chronic prostatitis] Zhonghua Nan Ke Xue. 2002;8(5):379-82.
Duan P, Wang ZM. [Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jul;22(7):515-7.
el Sebakhy NA, Asaad AM, Abdallah RM, et al. Antimicrobial isoflavans from Astragalus species. Phytochem 1994;36(6):1387-1389.
Fu QL. [Experimental study on Yiqi-huoxue therapy of liver fibrosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1992;12(4):228-9, 198.
Gariboldi P, Pelizzoni F, Tato M, et al. Cycloartane triterpene glycosides from Astragalus trigonus. Phytochem 1995;40(6):1755-1760.
Gu W, Yang YZ, He MX. [A study on combination therapy of Western and traditional Chinese medicine of acute viral myocarditis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1996;16(12):713-716.
Guo SK, Chen KJ, Yu FR, et al. Treatment of acute myocardial infarction with AMI-mixture combined with Western medicine. Planta Med 1983;48(1):63-64.
He Z, Findlay JA. Constituents of Astragalus membranaceus. J Natural Prod 1991;54(3):810-815.
Hikino H, Funayama S, Endo K. Hypotensive principle of Astragalus and Hedysarum roots. Planta Med 1976;30:297-302.
Hirotani M, Zhou Y, Rui H, et al. Cycloartane triterpene glycosides from the hairy root cultures of Astragalus membranaceus. Phytochem 1994;37(5):1403-1407.
Hong CY, Lo YC, Tan FC, et al. Astragalus membranaceus and Polygonum multiflorum protect rat heart mitochondria against lipid peroxidation. Am J Chinese Med 1994;22(1):63-70.
Hong GX, Qin WC, Huang LS. [Memory-improving effect of aqueous extract of Astragalus membranaceus (Fisch.) Bge.]. Zhongguo Zhong Yao Za Zhi 1994;19(11):687-8, 704.
Hou YD, Ma GL, Wu SH, et al. Effect of Radix Astragali seu Hedysari on the interferon system. Chin Med J (Engl ) 1981;94(1):35-40.
Huang WM, Yan J, Xu J. [Clinical and experimental study on inhibitory effect of Sanhuang mixture on platelet aggregation]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(8):465-467.
Huang ZQ, Qin NP, Ye W. [Effects of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(6):328-330.
Jin R, Wan LL, Mitsuishi T, et al. [Immunomodulative effects of Chinese herbs in mice treated with anti-tumor agent cyclophosphamide]. Yakugaku Zasshi 1994;114(7):533-538.
Kajimura K, Takagi Y, Ueba N, et al. Protective effect of astragali radix by oral administration against Japanese encephalitis virus infection in mice. Biol Pharm Bull 1996;19(9):1166-1169.
Khoo KS, Ang PT. Extract of Astragalus membranaceus and ligustrum lucidum does not prevent cyclophosphamide-induced myelosuppression. Singapore Med J 1995;36(4):387-390.
Kim C, Ha H, Kim JS, Kim YT, Kwon SC, Park SW. Induction of growth hormone by the roots of Astragalus membranaceus in pituitary cell culture. Arch Pharm Res. 2003 Jan;26(1):34-9.
Lau BH, Ruckle HC, Botolazzo T, et al. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother 1994;9(2):153-161.
Lei ZY, Qin H, Liao JZ. [Action of Astragalus membranaceus on left ventricular function of angina pectoris]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14(4):199-202.
Li CX, Li L, Lou J, et al. The protective effects of traditional Chinese medicine prescription, Han-dan-gan-le, on CCl4-induced liver fibrosis in rats. Am J Chin Med 1998;26(3-4):325-332.
Li L, Wang H, Zhu S. [Hepatic albumin's mRNA in nephrotic syndrome rats treated with Chinese herbs]. Zhonghua Yi Xue Za Zhi 1995;75(5):276-279.
Li NQ. [Clinical and experimental study on shen-qo injection with chemotherapy in the treatment of malignant tumor of digestive tract]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1992;12(10):579, 588-592.
Li X, et al. Pharmacological study of APS-G: Part 1 -- effect on reaction to stress. Zhong Cheng Yao 1989;11(3):27-29.
Li X, et al. Pharmacological study of APS-G: Part 3 -- effect on blood glucose and glycogen content in liver. Zhong Cheng Yao 1989;11(9):32-33.
Li C, Luo J, Li L, Cheng M, Huang N, Liu J, Waalkes MP. The collagenolytic effects of the traditional Chinese medicine preparation, Han-Dan-Gan-Le, contribute to reversal of chemical-induced liver fibrosis in rats. Life Sci. 2003 Feb 21;72(14):1563-71.
Liu ZG, Xiong ZM, Yu XY. [Effect of astragalus injection on immune function in patients with congestive heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 May;23(5):351-3.
Luo HM, Dai RH, Li Y. [Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(12):707-709.
Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of Astragalus membranaceus on sodium and water retention in experimental heart failure. Chin Med J 1998;111(1):17-23.
Ma Y, Tian Z, Kuang H, et al. Studies of the constituents of Astragalus membranaceus BUNGE. III. Structures of triterpenoidal glycosides, huangqiyenins A and B, from the leaves. Chem Pharm Bull 1997;45(2):359-361.
Ning L, Chen CX, Jin RM, Wu YP, Zhang HG, Sun CL, Song CQ, Hu ZB. [Effect of components of dang-gui-bu-xue decoction on hematopenia]. Zhongguo Zhong Yao Za Zhi. 2002 Jan;27(1):50-3.
Pan SY. [Pharmacological action of Astragalus membranaceus on the central nervous system in mice]. Zhong Yao Tong Bao 1986;11(9):47-49.
Qian ZW, Li YY. [Synergism of Astragalus membranaceus with interferon in the treatment of cervical erosion and their antiviral activities]. Zhong Xi Yi Jie He Za Zhi 1987;7(5):268-9, 287, 259.
Raghuprasad PK, Brooks SM, Litwin A, et al. Quillaja bark (soapbark)--induced asthma. J Allergy Clin Immunol 1980;65(4):285-287.
Rios JL, Waterman PG. A review of the pharmacology and toxicology of astragalus. Phytother Res 1997;11:411-418.
Rittenhouse JR, Lui PD, Lau BH. Chinese medicinal herbs reverse macrophage suppression induced by urological tumors. J Urol 1991;146(2):486-490.
Sheng ZL, Li NY, Ge XP. [Clinical study of baoyuan dahuang decoction in the treatment of chronic renal failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14(5):268-70, 259.
Shirataki Y, Takao M, Yoshida S, et al. Antioxidative components isolated from the roots of Astragalus membranaceus Bunge (Astragali Radix). Phytotherapy Res 1997;11:603-605.
Su ZZ, He YY, Chen G. [Clinical and experimental study on effects of Man-shen-ling oral liquid in the treatment of 100 cases of chronic nephritis]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 1993;13(5):269-60.
Sun Y, Hersh EM, Lee S, et al. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biological Response Modifiers 1983;2(3):227-237.
Sun Y, Hersh EM, Talpax M, et al. Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer 1983;52(1):70-73.
Sun Y. The role of traditional Chinese medicine in supportive care of cancer patients. Recent Results Cancer Res 1988;108:327-334.
Tianqing P, Yingzhen Y, Riesemann H, et al. The inhibitory effect of Astragalus membranaceus on coxsackie B-3 virus RNA replication. Chin Med Sciences J 1995;10(3):146-150.
Wang D, Shen W, Tian Y, et al. [Protective effect of total flavonoids of radix Astragali on mammalian cell damage caused by hydroxyl radical]. Zhongguo Zhong Yao Za Zhi 1995;20(4):240-2.
Wang F. Twenty-eight cases of diabetic foot ulcer and gangrene treated with the Chinese herbal medicine combined with injection of ahylsantinfarctase. J Tradit Chin Med. 2002 Mar;22(1):3-4.
Wang Q. [Inotropic action of Astragalus membranaceus Bge. saponins and its possible mechanism]. Zhongguo Zhong Yao Za Zhi 1992;17(9):557-559.
Wei H, Sun R, Xiao W, Feng J, Zhen C, Xu X, Tian Z. Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients. Oncol Rep. 2003 Sep-Oct;10(5):1507-12.
Weng XS. [Treatment of leucopenia with pure Astragalus preparation--an analysis of 115 leucopenic cases]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(8):462-464.
Wu XS, Chen HY, Li M. [Clinical observation on effect of combined use of Astragalus and compound salviae injection in treating acute cerebral infarction]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 May;23(5):380-1.
Xiangzhe J. A clinical investigation on 30 cases of senile benign renal arteriosclerosis treated by Huang qi gu jing yin. J Trad Chinese Med 2001;21(3):177-180.
Xu XY, Li LH, Wu LS, Zhao CL, Lin HY. [Adjustment effect of Dadix Astragalus and Dadix Angelicae sinensis on TNF-alpha and bFGF on renal injury induced by ischemia reperfusion in rabbit] Zhongguo Zhong Yao Za Zhi. 2002 Oct;27(10):771-3.
Xuan W, Dong M, Dong M. Effects of compound injection of Pyrola rotundifolia L. and Astragalus membranaceus Bge on experimental guinea pigs' gentamicin ototoxicity. Ann Otol Rhinol Laryngol 1995;104(5):374-380.
Yan HJ. [Clinical and experimental study of the effect of kang er xin-I on viral myocarditis]. Zhong Xi Yi Jie He Za Zhi 1991;11(8):468-70, 452.
Yang Y, Jin P, Guo Q, et al. Effect of Astragulas membranaceus on natural killer cell activity and induction of alpha- and gamma-interferon in patients with coxsackie B viral myocarditis. Chinese Med J 1990;103(4):304-307.
Yang Y, Jin P, Guo Q, et al. Treatment of experimental Coxsackie B-3 viral myocarditis with Astragalus membranaceus in mice. Chinese Med J 1990;103(1):14-18.
Yin X, Zhang S, Kong Y, et al. Observation on efficiency of Jiangtang capsule in treating diabetes mellitus type 2 with hyperlipidemia. Chinese J Integrated Trad Western Med 2001;7(3):214-216.
Yu L, Lu Y, Li J, Wang H. Identification of a gene associated with astragalus and angelica's renal protective effects by silver staining mRNA differential display. Chin Med J (Engl). 2002 Jun;115(6):923-7.
Yuan WL, Chen HZ, Yang YZ, et al. Effect of Astragalus membranaceus on electric activities of cultured rat beating heart cells infected with Coxsackie B-2 virus. Chin Med J 1990;103(3):177-182.
Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol 1992;14(9):725-736.
Zhang BZ, Ding F, Tan LW. [Clinical and experimental study on Yi-gan-ning granule in treating chronic hepatitis B]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993;13(10):597-9, 580.
Zhang H, Huang J. [Preliminary study of traditional Chinese medicine treatment of minimal brain dysfunction: analysis of 100 cases]. Zhong.Xi.Yi.Jie.He.Za Zhi. 1990;10(5):278-9, 260.
Zhang HE, et al. Treatment of adult diabetes with Jiangtangjia tablet. J Trad Chinese Med 1986;27(4):37-39.
Zhang WJ, Wojta J, Binder BR. Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: Astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression. J Vasc Res 1997;34:273-280.
Zhang YD, Shen JP, Zhu SH, et al. [Effects of astragalus (ASI, SK) on experimental liver injury]. Yao Xue.Xue.Bao. 1992;27(6):401-406.
Zhang ZL, Wen QZ, Liu CX. Hepatoprotective effects of astraglus root. J Ethnopharmacology 1990;30(2):145-149.
Zhang JG, Gao DS, Wei GH. [Clinical study on effect of Astragalus injection on left ventricular remodeling and left ventricular function in patients with acute myocardial infarction]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 May;22(5):346-8.
Zhao KS, Mancini C, Doria G. Enhancement of the immune response in mice by Astragalus membranaceus extracts. Immunopharmacology 1990;20(3):225-233.
Zhao KW, Kong HY. [Effect of Astragalan on secretion of tumor necrosis factors in human peripheral blood mononuclear cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993;13(5):263-5, 259.
Zhao XZ. [Effects of Astragalus membranaceus and Tripterygium hypoglancum on natural killer cell activity of peripheral blood mononuclear in systemic lupus erythematosus]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1992;12(11):669-71, 645.
Zhou Y, Hirotani M, Rui H, et al. Two triglycosidic triterpene astragalosides from hairy root cultures of Astragalus membranaceus. Phytochemistry 1995;38(6):1407-1410.
Zhou Y, Huang Z, Huang T, et al. Clinical study of Shengxue Mixture in treating aplastic anemia. Chin J Integ Trad West 2001;7(3):186-189.
Zong PP, Yan TY, Gong MM. [Clinical and experimental studies of effects of Huayu decoction on scavenging free radicals]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993;13(10):591-3, 579.
Zuo L, Guo H. [Quantitative study on synergistic effect of radix astragali A6 and acyclovir against herpes simplex virus type I by polymerase chain reaction]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998;18(4):233-235.
January 01, 2004

Astragalus (Astragalus membranaceus)

Astragalus (Astragalus membranaceus)


Background


Astragalus products are derived from the roots of Astragalus membranaceus or related species, which are native to China. In traditional Chinese medicine, astragalus is commonly found in mixtures with other herbs, and is used in the treatment of numerous ailments, including heart, liver, and kidney diseases, as well as cancer, viral infections, and immune system disorders. Western herbalists began using astragalus in the 1800s as an ingredient in various tonics. The use of astragalus became popular in the 1980s based on theories about anti-cancer properties, although these proposed effects have not been clearly demonstrated in reliable human studies.

Some medicinal uses of astragalus are based on its proposed immune stimulatory properties, reported in preliminary laboratory and animal experiments, but not conclusively demonstrated in humans. Most astragalus research has been conducted in China, and has not been well designed or reported.

Gummy sap (tragacanth) from astragalus is used as a thickener (ice cream), emulsifier, denture adhesive, and anti-diarrheal agent.

Synonyms


Astragalus trigonus, Astragalus gummifera, Astragalus mollissimus, Astragalus lentiginosus , astragel, baak kei, beg kei, bei qi, buck qi, Fabacea (family) , goat's horn, goat's thorn, green dragon, gum dragon, gum tragacanthae, gummi tragacanthae, hoang ky, hog gum, huang-chi, Huang Qi, huangoi, huangqi, hwanggi, ji cao, Leguminosae (family), locoweed, membranous milk vetch, milk vetch, mongolian milk, mongolian milk vetch, neimeng hhuangqi, ogi, ougi, radix astragali, spino santo, Syrian tragacanth, tai shen, tragacanth, wong kei, yellow vetch, Zhongfengnaomitong.

Selected combination products that include this agent : Astragalus-Power, Baoyuan Dahuang, Biomune OSF Plus, Bu Zhong Yi Qi Tang, CH-100, Chi Power, Chinese Thermo-Chi, Deep Defense, Energy Boost Tincture, Equi-lizer Fast Start, Excel Energy, Fast Start, Fit America Natural Weight Control Aid, Formula One, Formula 3, Formula 3 Cell Activator, Fu-Zheng, Han-Dan-Gan-Le, Herbal Balance, Intra, Jian Yan Ling (JYL), Jiangtangjia, Magic Herb Diet Plus Formula + Chromium Picolinate, Man-Shen-Ling (MSL), Master Herb with Chromium Picolinate, Megawatt, Nature's Nutrition Formula One, Nature's Power Trim Super Fat Burner, New Image, New Image Plus, Sanhuang, Shengxue Mixture (SXM), Shen-Qi, Shi-quan-da-bu-tang (SQT), Thermojetics Beige, Tri-Chromaleane, Ultra Energy Now, Vita Chromaleane, Yi-qi Huo-xue injection (YHI), Yogi Herbal Tea.

Evidence

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Uses based on scientific evidenceGrade*Cancer
Although early laboratory and animal studies report increased immune cell function and reduced cancer cell growth associated with the use of astragalus, there is no reliable human evidence in these areas. Due to a lack of well-designed research, a firm conclusion cannot be drawn.

C
Chemotherapy side effects
In Chinese medicine, astragalus-containing herbal mixtures are sometimes used with the intention to reduce side effects of cancer treatments. Due to a lack of well-designed research, a firm conclusion cannot be drawn.
C
Low white blood cell count
Astragalus has been suggested as an immune system stimulant in preliminary laboratory and animal research, and in traditional accounts. There are published reports from China of white blood cell counts increasing during the use of astragalus preparations, although details are limited. Reliable scientific study has not been conducted in this area. High quality human research is necessary before a firm conclusion can be drawn.
C
Immune stimulation
Astragalus has been suggested as an immune system stimulant in preliminary laboratory and animal research, and in traditional accounts. Reliable human studies are lacking. High quality human research is necessary before a firm conclusion can be drawn.
C
Anti-viral activity
Anti-viral activity has been reported with the use of astragalus in laboratory and animal studies. Limited human research has examined the use of astragalus for viral infections in the lung, heart (pericarditis), liver (hepatitis B and C), cervix (papilloma virus), and in HIV disease. Studies have included combinations of astragalus with the drug interferon, or as a part of herbal mixtures. However, most studies have been small and poorly designed. Due to a lack of well-designed research, no firm conclusions can be drawn.
C
Upper respiratory tract infection
Astragalus is often used in Chinese medicine as a part of herbal mixtures to prevent or treat upper respiratory tract infections. Anti-viral activity has been reported in laboratory and animal studies, and in limited human reports. However, most studies have been small and poorly designed. Due to a lack of well-designed research, no firm conclusions can be drawn.
C
Coronary artery disease
In Chinese medicine, herbal mixtures containing astragalus have been used to treat heart diseases. There are several human case reports of reduced symptoms and improved heart function, although these are not well described. High quality human research is necessary before a conclusion can be drawn.
C
Heart failure
In Chinese medicine, herbal mixtures containing astragalus have been used to treat various heart diseases. There are several human case reports of reduced symptoms and improved heart function, and diuretic ("water pill") effects, although these are not well described. High quality human research is necessary before a conclusion can be drawn.
C
Myocarditis/endocarditis (heart infections)
Anti-viral activity has been reported in laboratory studies and animal models of myocarditis/endocarditis. Human research is limited in this area, and further research is necessary before a conclusion can be drawn.
C
Renal failure
Several animal and human studies report that kidney damage from toxins and kidney failure may be improved with the use of astragalus-containing herbal mixtures. Overall, this research has been poorly designed and reported. Astragalus alone has not been well evaluated. Better quality research is necessary before a conclusion can be drawn.
C
Liver protection
Several animal and human studies report that astragalus may protect the liver from damage related to toxins or hepatitis B and C. Overall, this research has been poorly designed and reported. Astragalus alone has not been well evaluated. Better quality research is necessary before a conclusion can be drawn.
C
ya you betcha
* Key to grades
A: Strong scientific evidence for this use;
B: Good scientific evidence for this use;
C: Unclear scientific evidence for this use;
D: Fair scientific evidence against this use (it may not work);
F: Strong scientific evidence against this use (it likely does not work).


Uses based on tradition or theory
The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Adrenal insufficiency (Addison's disease), aging, AIDS/HIV, allergies, Alzheimer's disease, anemia, angina, ankylosing spondylitis, anorexia, antifungal, antimicrobial, antioxidant, asthma, blood thinner, bone-marrow suppression from cancer or HIV, bronchitis, cervicitis, "chi deficiency" (fatigue, weakness, loss of appetite), chronic fatigue syndrome, chronic hepatitis, cleanser, cyclosporine-induced immune suppression, dementia, demulcent, denture adhesive (astragalus sap), diabetes, diabetic foot ulcers, diabetic neuropathy, diarrhea, digestion enhancement, diuretic (urination stimulant), edema, fatigue, fever, gangrene, gastrointestinal disorders, genital herpes, graft-versus-host disease, hearing damage from toxins/gentamicin, heart attack, hemorrhage (bleeding), hemorrhoids, high cholesterol, high blood pressure, hyperthyroid, insomnia, joint pain, laxative, leprosy, leukemia, liver disease, low blood platelets, lung cancer, memory, menstrual disorders, metabolic disorders, minimal brain dysfunction, myalgia (muscle pain), myasthenia gravis, nephritis, night sweats, palpitations, pelvic congestion syndrome, postpartum fever, postpartum urinary retention, prostatitis, rectal prolapse, rotovirus enterocolitis (infants), shortness of breath, sperm motility, stamina/endurance enhancement, stomach ulcer, stroke, sweating (excessive), systemic lupus erythematosus (SLE), tissue oxygenation, uterine prolapse, uterine bleeding, weight loss, wound healing.

Dosing

The below doses are based on scientific research, publications, traditional use, or expert opinion. Many herbs and supplements have not been thoroughly tested, and safety and effectiveness may not be proven. Brands may be made differently, with variable ingredients, even within the same brand. The below doses may not apply to all products. You should read product labels, and discuss doses with a qualified healthcare provider before starting therapy.

Standardization

Standardization involves measuring the amount of certain chemicals in products to try to make different preparations similar to each other. It is not always known if the chemicals being measured are the "active" ingredients. Anecdotal reports have recommended astragalus to be standardized to a minimum of 0.4% 4-hydroxy-3-methoxy-isoflavone-7-glycoside per dose. However, since astragalus is often added to herbal mixtures with unclear amounts used, standardization is not always possible.

Adults (18 years and older)

General use by mouth : In Chinese medicine, astragalus is used in soups, teas, extracts, and pill form. In practice and in most scientific studies, astragalus is one component of multi-herb mixtures. Therefore, precise dosing of astragalus alone is not clear. Safety and effectiveness are not clearly established for any particular dose. Various doses of astragalus have been used or studied, including 250 to 500 milligrams of extract taken 4 times daily; 1 to 30 grams of dried root taken daily (doses as high as 60 grams have been reported); or 500 to 1000 milligrams of root capsules taken 3 times daily. Dosing of tinctures or fluid extracts depends on strength of preparations.

Note : In theory, consumption of the tragacanth (gummy sap derived from astragalus) may reduce absorption of drugs taken by mouth, and should be taken at separate times.

Children (younger than 18 years)

There is not enough scientific data to recommend astragalus for use in children.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Allergies

In theory, patients with allergies to members of the Leguminosae (pea) family may react to astragalus. Cross-reactivity with quillaja bark (soapbark) has been reported for astragalus gum tragacanth.

Side Effects and Warnings

Some species of astragalus have caused poisoning in livestock, although these types are usually not used in human preparations (which primarily include Astragalus membranaceus ). Livestock toxicity, referred to as "locoweed" poisoning, has occurred with species that contain swainsonine ( Astragalus lentiginosus, Astragalus mollissimus, Astragalus nothrosys, Astragalus pubentissimus, Astragalus thuseri, Astragalus wootoni ), or in species that accumulate selenium ( Astragalus bisulcatus, Astragalus flavus, Astragalus praelongus, Astragalus saurinus, Astragalus tenellus ).

Overall, it is difficult to determine the side effects or toxicity of astragalus, because it is most commonly used in combination with other herbs. There are numerous reports of side effects ranging from mild to deadly in the United States Food and Drug Administration computer database, although most of these are with multi-ingredient products, and cannot be attributed to astragalus specifically. Astragalus used alone and in recommended doses is traditionally considered to be safe, although safety is not well studied. The most common side effects appear to be mild stomach upset and allergic reactions. In the United States, tragacanth (astragalus gummy sap) has been classified as GRAS (generally recognized as safe) for food use, but astragalus does not have GRAS status.

Based on preliminary animal studies and limited human research, astragalus may decrease blood sugar levels. Caution is advised in patients with diabetes or hypoglycemia, and in those taking drugs, herbs, or supplements that affect blood sugar. Serum glucose levels may need to be monitored by a healthcare professional, and medication adjustments may be necessary.

Based on anecdotal reports and preliminary laboratory research, astragalus may increase the risk of bleeding. Caution is advised in patients with bleeding disorders or taking drugs that may increase the risk of bleeding. Dosing adjustments may be necessary.

Preliminary reports of human use in China have noted decreased blood pressure at doses below 15 grams and increased blood pressure at doses above 30 grams. Animal research suggests possible blood pressure lowering effects. Due to a lack of well-designed studies, no firm conclusions can be drawn. Nonetheless, people with abnormal blood pressure or taking blood pressure medications should use caution and be monitored by a qualified healthcare professional. Palpitations have been noted in human reports in China.

Based on animal study, astragalus may act as a diuretic and increase urination. In theory, this may lead to dehydration or metabolic abnormalities. There is one report of pneumonia in an infant after breathing in an herbal medicine powder including Astragalus sarcocolla .

Astragalus may increase growth hormone levels.

Pregnancy and Breastfeeding

There is not enough scientific evidence to recommend the safe use of Astragalus membranaceus during pregnancy or breastfeeding. Studies of toxic astragalus species, such as Astragalus lentiginosus or Astragalus mollissimus (locoweed) have reported harmful effects during animal pregnancies, leading to abortions or abnormal heart development.

References

Al-Fakhri SA. Herbal medicine: possible cause of aspiration pneumonia: A case report. Saudi Pharm J 1998;6(1):88-91.
Batey RG, Bensoussan A, Fan YY, et al. Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 1998;13(3):244-247.
Bedir E, Pugh N, Calis I, et al. Immunostimulatory effects of cycloartane-type triterpene glycosides from astragalus species. Biol Pharm Bull 2000;23(7):834-837.
Bisignano G, Iauk L, Kirjavainen S, et al. Anti-inflammatory, analgesic, antipyretic and antibacterial activity of Astragalus siculus biv. Int J Pharm 1994;32(4):400-405.
Burack JH, Cohen MR, Hahn JA, et al. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(4):386-393.
Chen KT, Su CH, Hsin LH, Su YC, Su YP, Lin JG. Reducing fatigue of athletes following oral administration of huangqi jianzhong tang. Acta Pharmacol Sin. 2002 Aug;23(8):757-61.
Chen LX, Liao JZ, Guo WQ. [Effects of Astragalus membranaceus on left ventricular function and oxygen free radical in acute myocardial infarction patients and mechanism of its cardiotonic action]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(3):141-143.
Chu DT, Lepe-Zuniga J, Wong WL, et al. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. J Clin Lab Immunol 1988;26(4):183-187.
Chu DT, Lin JR, Wong W. [The in vitro potentiation of LAK cell cytotoxicity in cancer and AIDS patients induced by F3--a fractionated extract of Astragalus membranaceus]. Zhonghua Zhong.Liu Za Zhi. 1994;16(3):167-171.
Chu DT, Sun Y, Lin JR. [Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients in vitro and reversal of cyclophosphamide-induced immune suppression in the rat in vivo by fractionated Astragalus membranaceus]. Zhong Xi Yi Jie He Za Zhi 1989;9(6):351-4, 326.
Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J Clin Lab Immunol 1988;25(3):125-129.
Coppes MJ, Anderson RA, Egeler RM, et al. Alternative therapies for the treatment of childhood cancer. N Engl J Med 1998;339 (12) :846-847.
Cuellar M, Giner RM, Recio MC, et al. Screening of antiinflammatory medicinal plants used in traditional medicine against skin diseases. Phytother Res 1998;12:18-23.
Cui R, He J, Wang B, Zhang F, Chen G, Yin S, Shen H. Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother Pharmacol. 2003 Jan;51(1):75-80. Epub 2002 Nov 26.
Dai CF, Zhang ZZ, Qi XL, Zhang MX, Li YP. [Clinical and experimental study of treatment of nanmiqing capsule for chronic prostatitis] Zhonghua Nan Ke Xue. 2002;8(5):379-82.
Duan P, Wang ZM. [Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jul;22(7):515-7.
el Sebakhy NA, Asaad AM, Abdallah RM, et al. Antimicrobial isoflavans from Astragalus species. Phytochem 1994;36(6):1387-1389.
Fu QL. [Experimental study on Yiqi-huoxue therapy of liver fibrosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1992;12(4):228-9, 198.
Gariboldi P, Pelizzoni F, Tato M, et al. Cycloartane triterpene glycosides from Astragalus trigonus. Phytochem 1995;40(6):1755-1760.
Gu W, Yang YZ, He MX. [A study on combination therapy of Western and traditional Chinese medicine of acute viral myocarditis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1996;16(12):713-716.
Guo SK, Chen KJ, Yu FR, et al. Treatment of acute myocardial infarction with AMI-mixture combined with Western medicine. Planta Med 1983;48(1):63-64.
He Z, Findlay JA. Constituents of Astragalus membranaceus. J Natural Prod 1991;54(3):810-815.
Hikino H, Funayama S, Endo K. Hypotensive principle of Astragalus and Hedysarum roots. Planta Med 1976;30:297-302.
Hirotani M, Zhou Y, Rui H, et al. Cycloartane triterpene glycosides from the hairy root cultures of Astragalus membranaceus. Phytochem 1994;37(5):1403-1407.
Hong CY, Lo YC, Tan FC, et al. Astragalus membranaceus and Polygonum multiflorum protect rat heart mitochondria against lipid peroxidation. Am J Chinese Med 1994;22(1):63-70.
Hong GX, Qin WC, Huang LS. [Memory-improving effect of aqueous extract of Astragalus membranaceus (Fisch.) Bge.]. Zhongguo Zhong Yao Za Zhi 1994;19(11):687-8, 704.
Hou YD, Ma GL, Wu SH, et al. Effect of Radix Astragali seu Hedysari on the interferon system. Chin Med J (Engl ) 1981;94(1):35-40.
Huang WM, Yan J, Xu J. [Clinical and experimental study on inhibitory effect of Sanhuang mixture on platelet aggregation]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(8):465-467.
Huang ZQ, Qin NP, Ye W. [Effects of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(6):328-330.
Jin R, Wan LL, Mitsuishi T, et al. [Immunomodulative effects of Chinese herbs in mice treated with anti-tumor agent cyclophosphamide]. Yakugaku Zasshi 1994;114(7):533-538.
Kajimura K, Takagi Y, Ueba N, et al. Protective effect of astragali radix by oral administration against Japanese encephalitis virus infection in mice. Biol Pharm Bull 1996;19(9):1166-1169.
Khoo KS, Ang PT. Extract of Astragalus membranaceus and ligustrum lucidum does not prevent cyclophosphamide-induced myelosuppression. Singapore Med J 1995;36(4):387-390.
Kim C, Ha H, Kim JS, Kim YT, Kwon SC, Park SW. Induction of growth hormone by the roots of Astragalus membranaceus in pituitary cell culture. Arch Pharm Res. 2003 Jan;26(1):34-9.
Lau BH, Ruckle HC, Botolazzo T, et al. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biother 1994;9(2):153-161.
Lei ZY, Qin H, Liao JZ. [Action of Astragalus membranaceus on left ventricular function of angina pectoris]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14(4):199-202.
Li CX, Li L, Lou J, et al. The protective effects of traditional Chinese medicine prescription, Han-dan-gan-le, on CCl4-induced liver fibrosis in rats. Am J Chin Med 1998;26(3-4):325-332.
Li L, Wang H, Zhu S. [Hepatic albumin's mRNA in nephrotic syndrome rats treated with Chinese herbs]. Zhonghua Yi Xue Za Zhi 1995;75(5):276-279.
Li NQ. [Clinical and experimental study on shen-qo injection with chemotherapy in the treatment of malignant tumor of digestive tract]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1992;12(10):579, 588-592.
Li X, et al. Pharmacological study of APS-G: Part 1 -- effect on reaction to stress. Zhong Cheng Yao 1989;11(3):27-29.
Li X, et al. Pharmacological study of APS-G: Part 3 -- effect on blood glucose and glycogen content in liver. Zhong Cheng Yao 1989;11(9):32-33.
Li C, Luo J, Li L, Cheng M, Huang N, Liu J, Waalkes MP. The collagenolytic effects of the traditional Chinese medicine preparation, Han-Dan-Gan-Le, contribute to reversal of chemical-induced liver fibrosis in rats. Life Sci. 2003 Feb 21;72(14):1563-71.
Liu ZG, Xiong ZM, Yu XY. [Effect of astragalus injection on immune function in patients with congestive heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 May;23(5):351-3.
Luo HM, Dai RH, Li Y. [Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(12):707-709.
Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of Astragalus membranaceus on sodium and water retention in experimental heart failure. Chin Med J 1998;111(1):17-23.
Ma Y, Tian Z, Kuang H, et al. Studies of the constituents of Astragalus membranaceus BUNGE. III. Structures of triterpenoidal glycosides, huangqiyenins A and B, from the leaves. Chem Pharm Bull 1997;45(2):359-361.
Ning L, Chen CX, Jin RM, Wu YP, Zhang HG, Sun CL, Song CQ, Hu ZB. [Effect of components of dang-gui-bu-xue decoction on hematopenia]. Zhongguo Zhong Yao Za Zhi. 2002 Jan;27(1):50-3.
Pan SY. [Pharmacological action of Astragalus membranaceus on the central nervous system in mice]. Zhong Yao Tong Bao 1986;11(9):47-49.
Qian ZW, Li YY. [Synergism of Astragalus membranaceus with interferon in the treatment of cervical erosion and their antiviral activities]. Zhong Xi Yi Jie He Za Zhi 1987;7(5):268-9, 287, 259.
Raghuprasad PK, Brooks SM, Litwin A, et al. Quillaja bark (soapbark)--induced asthma. J Allergy Clin Immunol 1980;65(4):285-287.
Rios JL, Waterman PG. A review of the pharmacology and toxicology of astragalus. Phytother Res 1997;11:411-418.
Rittenhouse JR, Lui PD, Lau BH. Chinese medicinal herbs reverse macrophage suppression induced by urological tumors. J Urol 1991;146(2):486-490.
Sheng ZL, Li NY, Ge XP. [Clinical study of baoyuan dahuang decoction in the treatment of chronic renal failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14(5):268-70, 259.
Shirataki Y, Takao M, Yoshida S, et al. Antioxidative components isolated from the roots of Astragalus membranaceus Bunge (Astragali Radix). Phytotherapy Res 1997;11:603-605.
Su ZZ, He YY, Chen G. [Clinical and experimental study on effects of Man-shen-ling oral liquid in the treatment of 100 cases of chronic nephritis]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 1993;13(5):269-60.
Sun Y, Hersh EM, Lee S, et al. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biological Response Modifiers 1983;2(3):227-237.
Sun Y, Hersh EM, Talpax M, et al. Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer 1983;52(1):70-73.
Sun Y. The role of traditional Chinese medicine in supportive care of cancer patients. Recent Results Cancer Res 1988;108:327-334.
Tianqing P, Yingzhen Y, Riesemann H, et al. The inhibitory effect of Astragalus membranaceus on coxsackie B-3 virus RNA replication. Chin Med Sciences J 1995;10(3):146-150.
Wang D, Shen W, Tian Y, et al. [Protective effect of total flavonoids of radix Astragali on mammalian cell damage caused by hydroxyl radical]. Zhongguo Zhong Yao Za Zhi 1995;20(4):240-2.
Wang F. Twenty-eight cases of diabetic foot ulcer and gangrene treated with the Chinese herbal medicine combined with injection of ahylsantinfarctase. J Tradit Chin Med. 2002 Mar;22(1):3-4.
Wang Q. [Inotropic action of Astragalus membranaceus Bge. saponins and its possible mechanism]. Zhongguo Zhong Yao Za Zhi 1992;17(9):557-559.
Wei H, Sun R, Xiao W, Feng J, Zhen C, Xu X, Tian Z. Traditional Chinese medicine Astragalus reverses predominance of Th2 cytokines and their up-stream transcript factors in lung cancer patients. Oncol Rep. 2003 Sep-Oct;10(5):1507-12.
Weng XS. [Treatment of leucopenia with pure Astragalus preparation--an analysis of 115 leucopenic cases]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15(8):462-464.
Wu XS, Chen HY, Li M. [Clinical observation on effect of combined use of Astragalus and compound salviae injection in treating acute cerebral infarction]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003 May;23(5):380-1.
Xiangzhe J. A clinical investigation on 30 cases of senile benign renal arteriosclerosis treated by Huang qi gu jing yin. J Trad Chinese Med 2001;21(3):177-180.
Xu XY, Li LH, Wu LS, Zhao CL, Lin HY. [Adjustment effect of Dadix Astragalus and Dadix Angelicae sinensis on TNF-alpha and bFGF on renal injury induced by ischemia reperfusion in rabbit] Zhongguo Zhong Yao Za Zhi. 2002 Oct;27(10):771-3.
Xuan W, Dong M, Dong M. Effects of compound injection of Pyrola rotundifolia L. and Astragalus membranaceus Bge on experimental guinea pigs' gentamicin ototoxicity. Ann Otol Rhinol Laryngol 1995;104(5):374-380.
Yan HJ. [Clinical and experimental study of the effect of kang er xin-I on viral myocarditis]. Zhong Xi Yi Jie He Za Zhi 1991;11(8):468-70, 452.
Yang Y, Jin P, Guo Q, et al. Effect of Astragulas membranaceus on natural killer cell activity and induction of alpha- and gamma-interferon in patients with coxsackie B viral myocarditis. Chinese Med J 1990;103(4):304-307.
Yang Y, Jin P, Guo Q, et al. Treatment of experimental Coxsackie B-3 viral myocarditis with Astragalus membranaceus in mice. Chinese Med J 1990;103(1):14-18.
Yin X, Zhang S, Kong Y, et al. Observation on efficiency of Jiangtang capsule in treating diabetes mellitus type 2 with hyperlipidemia. Chinese J Integrated Trad Western Med 2001;7(3):214-216.
Yu L, Lu Y, Li J, Wang H. Identification of a gene associated with astragalus and angelica's renal protective effects by silver staining mRNA differential display. Chin Med J (Engl). 2002 Jun;115(6):923-7.
Yuan WL, Chen HZ, Yang YZ, et al. Effect of Astragalus membranaceus on electric activities of cultured rat beating heart cells infected with Coxsackie B-2 virus. Chin Med J 1990;103(3):177-182.
Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol 1992;14(9):725-736.
Zhang BZ, Ding F, Tan LW. [Clinical and experimental study on Yi-gan-ning granule in treating chronic hepatitis B]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993;13(10):597-9, 580.
Zhang H, Huang J. [Preliminary study of traditional Chinese medicine treatment of minimal brain dysfunction: analysis of 100 cases]. Zhong.Xi.Yi.Jie.He.Za Zhi. 1990;10(5):278-9, 260.
Zhang HE, et al. Treatment of adult diabetes with Jiangtangjia tablet. J Trad Chinese Med 1986;27(4):37-39.
Zhang WJ, Wojta J, Binder BR. Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: Astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression. J Vasc Res 1997;34:273-280.
Zhang YD, Shen JP, Zhu SH, et al. [Effects of astragalus (ASI, SK) on experimental liver injury]. Yao Xue.Xue.Bao. 1992;27(6):401-406.
Zhang ZL, Wen QZ, Liu CX. Hepatoprotective effects of astraglus root. J Ethnopharmacology 1990;30(2):145-149.
Zhang JG, Gao DS, Wei GH. [Clinical study on effect of Astragalus injection on left ventricular remodeling and left ventricular function in patients with acute myocardial infarction]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 May;22(5):346-8.
Zhao KS, Mancini C, Doria G. Enhancement of the immune response in mice by Astragalus membranaceus extracts. Immunopharmacology 1990;20(3):225-233.
Zhao KW, Kong HY. [Effect of Astragalan on secretion of tumor necrosis factors in human peripheral blood mononuclear cells]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993;13(5):263-5, 259.
Zhao XZ. [Effects of Astragalus membranaceus and Tripterygium hypoglancum on natural killer cell activity of peripheral blood mononuclear in systemic lupus erythematosus]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1992;12(11):669-71, 645.
Zhou Y, Hirotani M, Rui H, et al. Two triglycosidic triterpene astragalosides from hairy root cultures of Astragalus membranaceus. Phytochemistry 1995;38(6):1407-1410.
Zhou Y, Huang Z, Huang T, et al. Clinical study of Shengxue Mixture in treating aplastic anemia. Chin J Integ Trad West 2001;7(3):186-189.
Zong PP, Yan TY, Gong MM. [Clinical and experimental studies of effects of Huayu decoction on scavenging free radicals]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1993;13(10):591-3, 579.
Zuo L, Guo H. [Quantitative study on synergistic effect of radix astragali A6 and acyclovir against herpes simplex virus type I by polymerase chain reaction]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998;18(4):233-235.
January 01, 2004

Wednesday, July 06, 2005

Arginine (L-Arginine)

Arginine (L-Arginine)


Background


L-arginine was first isolated in 1886. In 1932, L-arginine was found to be required for the generation of urea, which is necessary for the removal of toxic ammonia from the body. In 1939, L-arginine was also shown to be required for the synthesis of creatine. Creatine degrades to creatinine at a constant rate, and is cleared from the body by the kidney.

Arginine is considered a semi-essential amino acid, because although it is normally synthesized in sufficient amounts by the body, supplementation is sometimes required (for example, due to inborn errors of urea synthesis, protein malnutrition, excess ammonia production, excessive lysine intake, burns, infection, peritoneal dialysis, rapid growth, or sepsis). Symptoms of arginine deficiency include poor wound healing, hair loss, skin rash, constipation, and fatty liver.

Arginine is a precursor of nitric oxide, which causes blood vessel relaxation (vasodilation). Preliminary evidence suggests that arginine may be useful in the treatment of medical conditions that are improved by vasodilation, such as angina, atherosclerosis, coronary artery disease, erectile dysfunction, heart failure, intermittent claudication/peripheral vascular disease, and vascular headache. Arginine also stimulates protein synthesis and has been studied for wound healing, bodybuilding, enhancement of sperm production (spermatogenesis), and prevention of wasting in people with critical illness.

Arginine hydrochloride contains high chloride content and has been used for the treatment of metabolic alkalosis. This use should be under the supervision of a qualified healthcare professional.

Most people likely do not need to take arginine supplements because the body usually makes sufficient amounts.

Synonyms


Arg, arginine, arginine hydrochloride (intravenous formulation), ibuprofen-arginate (Spedifen®), L-arginine, 2-amino-5-guanidinopentanoic acid.

Note : Arginine vasopressin is different from arginine/L-arginine, with an entirely different mechanism. NG-monomethyl-L-arginine is different from arginine/L-arginine, and functions as an inhibitor of nitric oxide synthesis.

Dietary sources of arginine : Walnuts, filberts, pecans, Brazil nuts, sesame and sunflower seeds, brown rice, raisins, coconut, gelatin, buckwheat, almonds, barley, cashews, cereals, chicken, chocolate, corn, dairy products, meats, oats, peanuts.

Evidence

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Uses based on scientific evidenceGrade*Growth hormone reserve test / pituitary disorder diagnosis
Intravenously administered arginine can be used to evaluate growth hormone reserve in individuals with suspected growth hormone deficiency. For example, in patients with suspected panhypopituitarism, growth/stature abnormalities, gigantism/acromegaly, or pituitary adenoma. This is an FDA labeled indication for arginine.

A
Inborn errors of urea synthesis
In patients with inborn errors of urea synthesis, high blood ammonia levels and metabolic alkalosis may occur, particularly in patients with ornithine carbamoyl transferase (OCT) deficiency or carbomoyl phosphate synthetase (CPS) deficiency. Arginine can be a helpful treatment by shifting the way the body processes nitrogen, but should be avoided in patients with hyperargininemia (high arginine levels). Other drugs may have similar benefits, such as citrulline, sodium benzoate, or sodium phenylbutyrate, although dialysis may be necessary initially. This use of arginine should be supervised by a qualified healthcare professional.
A
Adrenoleukodystrophy (ALD)
Adrenoleukodystrophy (ALD) is a rare inherited metabolic disorder characterized by the loss of fatty coverings (myelin sheaths) on nerve fibers in the brain, and progressive destruction of the adrenal gland. ALD is inherited as an x-linked genetic trait that results in dementia and adrenal failure. Injections of arginine have been proposed to help manage this disorder, although most study results are inconclusive. Further research is needed to evaluate the use of arginine in ALD.
C
Burns
A randomized, controlled clinical trial designed to evaluate immune function of patients given 15mg of arginine orally suggests that arginine may help with the recovery of immune function and protein function in partial-thickness burn patients. Further research is necessary in this area before a conclusion can be drawn.
C
Coronary artery disease / angina
There is initial evidence from several studies that arginine taken by mouth or by injection improves exercise tolerance and blood flow in arteries of the heart. Benefits have been shown in some patients with coronary artery disease and angina. A small randomized, controlled clinical trial studied the effects of a medical food bar enriched with L-arginine and a combination of other nutrients in the management of chronic stable angina. The authors found that this arginine-rich medical food, when used with traditional therapy, improves vascular function, exercise capacity and aspects of quality of life in these patients. However, further research is needed to confirm these findings and to establish doses that may be safe and effective.
C
Critical illness
Some studies suggest that arginine may provide benefits when added to nutritional supplements during critical illnesses (for example, in patients being treated in intensive care units). However, it is unclear what the specific role of arginine may be in improving recovery. A randomized, controlled clinical trial was designed to study the effects of a high-protein formula enriched with arginine, fiber, and antioxidants in early nutrition therapy of critically ill patients. The study measured infections in the hospital intensive care unit (ICU), length of hospital stay, and death rates. Patients fed the high-protein diet enriched with arginine, fiber and antioxidants developed fewer hospital infections than patients fed a standard high-protein diet. There was no difference in length of ICU hospital stay or death rate.
C
Dental pain (ibuprofen arginate)
A well-designed multicenter, randomized controlled clinical trial found that ibuprofen-arginate (Spedifen®) reduced pain faster after dental surgery compared to conventional ibuprofen alone. The study included 498 patients who were given either ibuprofen-arginate, ibuprofen, or placebo after dental surgery. The degree of the relief of pain, onset of action, and tolerability of both ibuprofen-arginate and ibuprofen were compared. It was found that ibuprofen arginate relieved pain faster and adverse events with ibuprofen arginate were similar to those seen with ibuprofen alone. Another similar trial concluded that patients treated with ibuprofen arginate rated its overall effectiveness higher than those treated with ibuprofen alone. Adverse event profiles were similar across all treatment groups. Further research is merited in this area.
C
Erectile dysfunction
Early studies propose that men with low nitrate levels in their blood or urine may find arginine supplements to be useful for managing erectile dysfunction (ED). A randomized, controlled clinical trial reported improvements in patients with mild-to-moderate ED following use of a combination of L-arginine, glutamate and yohimbine hydrochloride. Notably, yohimbine hydrochloride is an FDA-approved therapy for this condition, and the effects caused by arginine alone in this combination therapy are difficult to determine. It is not clear what doses of arginine may be safe or effective in treating this condition, and comparisons have not been made with other agents used for ED.
C
Gastrointestinal cancer surgery
Supplementation with an oral combination of arginine and omega-3 fatty acids may reduce length of hospital stay and infections after surgery in gastrointestinal cancer patients. There is conflicting evidence as to when to give the combination (either before or after surgery). Both strategies have been reported as superior to conventional treatment (no artificial nutrition) at reducing infections after surgery and reducing hospital stay. In a large, randomized, controlled clinical trial, malnourished cancer patients were given oral enteral nutrition supplemented by arginine, omega-3 fatty acids and RNA before surgery. It was found that supplementation with the combination before surgery reduced complications after surgery and hospital stay. A different randomized, controlled clinical trial in patients with gastrointestinal cancer studied the effects of an enteral diet supplemented with arginine, omega-3 fatty acids and glutamine (administered after surgery) on immune function and inflammatory response. This study reported the supplement to be well-tolerated with positive effects on immune and inflammatory response. Further research is needed to determine the possible effects of arginine alone.
C
Heart failure (CHF)
Studies of arginine in patients with chronic heart failure have shown mixed results. Some studies report improved exercise tolerance. Additional studies are needed to confirm these findings before a firm conclusion can be drawn.
C
Heart protection during coronary artery bypass grafting (CABG)
Arginine-supplemented "blood cardioplegic solution" is proposed to have protective properties for the heart. A randomized, controlled clinical trial using this solution in patients undergoing heart surgery (coronary artery bypass grafting) reports improved heart protection. Further research is needed before a firm conclusion can be drawn.
C
High blood pressure
A small study suggests that arginine taken by mouth may help to dilate the arteries and temporarily reduce blood pressure in hypertensive patients with type 2 diabetes. Larger, high-quality studies are needed before a recommendation can be made.
C
Migraine headache
Preliminary studies suggest that adding arginine to ibuprofen therapy may decrease migraine headache pain.
C
Peripheral vascular disease / claudication
Intermittent claudication is a condition characterized by leg pain and fatigue due to buildup of cholesterol plaques or clots in leg arteries. A small number of studies report that arginine therapy may improve walking distance in patients with claudication. Further research is needed before a firm conclusion can be drawn.
C
Recovery after surgery
One study suggests that arginine may provide benefits when used as a supplement after surgery. It is not clear what the specific role of arginine may be in improving immune function, or what dose is safe or effective.
C
Wound healing
Arginine has been suggested to improve the rate of wound healing in elderly individuals. A randomized, controlled clinical trial reported improved wound healing after surgery in head and neck cancer patients, following the use of an enteral diet supplemented with arginine and fiber. Arginine has also been used topically (on the skin) to attempt to improve wound healing. Further research is necessary in this area before a firm conclusion can be drawn.
C
Kidney disease
It has been suggested that arginine may be a useful supplement in people diagnosed with kidney failure. However, results from available studies do not support this claim. A small randomized, controlled clinical trial studied the ability of L-arginine to improve dilation of blood vessels in children with chronic renal failure. Results showed that blood vessel dilation (endothelial function) was not improved with oral L-arginine suggesting that dietary supplementation is not a beneficial or useful clinical approach in children with chronic renal failure.
D
Kidney protection during angiography
The contrast media or dye used during angiography to map a patient's arteries (or during some CT scans) can be toxic to the kidneys, especially to people with pre-existing kidney disease. A randomized, parallel, double-blind clinical trial studied the use of L-arginine to protect kidneys in patients with chronic renal failure undergoing angiography. The authors found no evidence that injections of L-arginine protect the kidney from damage due to contrast. Other therapies, such as N-acetylcysteine (NAC), have been found beneficial at protecting the kidneys from contrast-induced damage, particularly in patients at high-risk such as those with diabetes.
D
Cyclosporine toxicity
Animal studies report that arginine blocks the toxic effects of cyclosporine, a drug used to prevent organ transplant rejection. However, results from studies in humans have not found that arginine offers any protection from cyclosporine-induced toxicity.
D
Infertility
Although there are several studies in this area, it is not clear what effects arginine has on improving the likelihood of getting pregnant. Early evidence does not support the finding that arginine has any benefits in women who are undergoing in vitro fertilization, or in men with abnormal sperm.
D
Interstitial cystitis
Arginine has been proposed as a treatment for interstitial cystitis (inflammation of the bladder). However, most well-designed studies in humans have not found that arginine offers any improvements in treating symptoms such as urinary frequency or urgency.
D
Asthma
Although it has been suggested that arginine may be a treatment for asthma, studies in humans have actually found that arginine worsens inflammation in the lungs and contributes to asthma symptoms. Therefore, taking arginine by mouth or by inhalation is not recommended in people with asthma.
F
* Key to grades
A: Strong scientific evidence for this use;
B: Good scientific evidence for this use;
C: Unclear scientific evidence for this use;
D: Fair scientific evidence against this use (it may not work);
F: Strong scientific evidence against this use (it likely does not work).


Uses based on tradition or theory
The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

AIDS/HIV, ammonia toxicity, anti-aging, beta-hemoglobinopathies, cancer, cardiac syndrome X, cold prevention, cystic fibrosis, dementia, diabetes, enhanced athletic performance, enhanced immune function, glaucoma, growth hormone stimulation, heart attack, hemolytic uremic syndrome (HUS), hepatic encephalopathy, immunomodulation, infection, pulmonary hypertension (high blood pressure in the lungs), high cholesterol, increased muscle mass, infantile necrotizing enterocolitis, inflammatory bowel disease, ischemic stroke, liver disease, lower esophageal sphincter relaxation, low sperm count, metabolic acidosis, obesity, osteoporosis, pain, peritonitis, preeclampsia, pre-term labor contractions, Raynaud's phenomenon, sepsis, sickle cell anemia, stomach motility disorders, stomach ulcer, stroke, supplementation to a low protein diet, thrombotic thrombocytopenic purpura (TTP).

Dosing

The below doses are based on scientific research, publications, traditional use, or expert opinion. Many herbs and supplements have not been thoroughly tested, and safety and effectiveness may not be proven. Brands may be made differently, with variable ingredients, even within the same brand. The below doses may not apply to all products. You should read product labels, and discuss doses with a qualified healthcare provider before starting therapy.

Standardization:

Intravenous arginine hydrochloride is available as a 10% solution (950 mOsm/L), winth 47.5mEq chloride ion per 100mL. There is no established standardization for oral arginine products.

Note : Most people likely do not need to take arginine supplements because the body usually makes sufficient amounts.

Adults (18 years and older):

Tablets/capsules: There are no standard or well-established doses of arginine, and many different doses have been used and studied. A dose that has been studied for treating coronary artery disease is two to three grams taken by mouth three times daily for three to six months. A studied dose for heart failure is 5.6 to 12.6 grams taken by mouth every day, divided into two or three equal doses, taken for six weeks. For erectile dysfunction, 1.6 grams taken by mouth three times daily for six weeks has been studied. For low sperm count, four grams daily for three months has been used. For women undergoing in vitro (test tube) fertilization, a dose of 16 grams daily by mouth has been studied, although this therapy should be discussed with the healthcare provider coordinating the in vitro program. For interstitial cystitis, 500 milligrams taken by mouth three times daily for six weeks has been used. For the long-term management of inborn disorders of the urea cycle, doses between 0.5 to 2 grams daily have been used.

Intravenous: Doses of arginine used intravenously depend on specific institutional dosing guidelines and should be given under the supervision of a healthcare provider.

Children (younger than 18 years):

Arginine supplements are not recommended in children because there is not enough scientific information available and because of potential side effects.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Allergies

Anaphylaxis (severe allergic reaction) has occurred after arginine injections. People with a known allergy should avoid arginine. Signs of allergy may include rash, itching or shortness of breath.

Side Effects and Warnings

Arginine has been well tolerated by most people in studies lasting for up to six months, although there is a possibility of serious adverse effects in some individuals.

Stomach discomfort, including nausea, stomach cramps or an increased number of stools, may occur. People with asthma may experience a worsening of symptoms if arginine is inhaled, which may be related to allergy.

Other potential side effects include low blood pressure and changes in numerous chemicals and electrolytes in the blood. Examples include high potassium, high chloride, low sodium, low phosphate, high blood urea nitrogen and high creatinine levels. People with liver or kidney disease may be especially sensitive to these complications and should avoid using arginine except under medical supervision. After injections of arginine, low back pain, flushing, headache, numbness, restless legs, venous irritation and death of surrounding tissues have been reported.

In theory, arginine may increase the risk of bleeding. Patients using anticoagulants (blood thinners) or antiplatelet drugs, or with underlying bleeding disorders, should speak with a qualified healthcare provider before using arginine and should be monitored.

Arginine may increase blood sugar levels. Caution is advised in patients taking prescription drugs to control sugar levels.

Pregnancy and Breastfeeding

Arginine cannot be recommended as a supplement during pregnancy and breast-feeding because there is not enough scientific information available.

References

Bath PM, Willmot M Leonardi-Bee J, et al. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochrane Database Syst Rev 2002;(4): CD000398.
Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med 1999;27 (12) :2799-2805.
Bennett-Richards KJ, Kattenhorn M, Donald AE, et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002;62(4): 1372-1378.
Black P, Max MB' Desjardins P, Norwood T, et al. A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain. Clin Ther 2002;24(7): 1072-1089.
Boger RH, Bode-Boger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32(5):1336-1344.
Braga M, Gianotti L, Nespoli L, Radaelli G, et al. Nutritional approach in malnourished surgical patients: a prospective randomized study. Arch Surg 2002;137(2): 174-80.
Caparros T, Lopez J, Grau T. Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections and outcome. JPEN J Parenter Enteral Nutr 2001;25(6):299-308; discussion 308-309.
Carrier M, Pellerin M, Perrault LP, et al. Cardioplegic arrest with L-arginine improves myocardial protection: results of a prospective randomized clinical trial. Ann Thorac Surg 2002; 73(3): 837-41; discussion 842.
Cartledge JJ, Davies AM, Eardley I. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. BJU Int 2000;85(4):421-426.
Cen Y, Luo XS, Liu XX. Effect of L-arginine supplementation on partial-thickness burned patients. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1999;13(4):227-231.
Chen J, Wollman Y, Chernichovsky T, et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double- blind, randomized, placebo-controlled study. BJU Int 1999;83(3):269-273.
Chuntrasakul C, Siltharm S, Sarasombath S, et al. Metabolic and immune effects of dietary arginine, glutamine and omega-3 fatty acids supplementation in immunocompromised patients. J Med Assoc Thai 1998;81(5):334-343.
de Luis DA, Aller R, Izaola O, et al. Postsurgery enteral nutrition in head and neck cancer patients. Eur J Clin Nutr 2002;56(11):1126-1129.
de Luis DA, Izaola O, Cuellar L, et al. Effects of c-reactive protein and interleukins blood levels in postsurgery arginine-enhanced enteral nutrition in head and neck cancer patients. Eur J Clin Nutr 2003;57(1):96-99.
Desjardins P, Black P, Papageorge M, et al. Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen. Eur J Clin Pharmacol 2002;58(6):387-94.
Gianotti L, Braga M, Nespoli L, et al. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gasterointestinal cancer. Evid Based Nurs 2003;6(2):47.
Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr 2002;21(5):422-427.
Klotz T, Mathers MJ, Braun M, et al. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 1999;63(4):220-223.
Korting G, Smith S, Wheeler M, et al. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol 1999;161(2):558-565.
Lebret T, Herve JM, Gorny P, et al. Efficacy and safety of a novel combination of L-arginine, glutamate, and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol 2002;41(6):608-613.
Lekakis JP, Papathanassiou S, Papioannou TG, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002;86(2-3):317-323.
Maxwell AJ, Zapien MP, Pearce GL, et al. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol 2002;39(1):37-45.
McGovern MM, Wasserstein MP, Aron A, et al. Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy. J Pediatr. 2003;142(6):709-713.
Mehlisch DR, Ardia A, Pallotta T. A controlled comparative study of ibuprofen arginate versus conventional ibuprofen in the treatment of postoperative dental pain. J Clin Pharmacol 2002;42(8):904-911.
Miller HI, Dascalu A, Rassin TA, et al. Effects of an acute dose of L-arginine during coronary angiography in patients with chronice renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol 2003;23(2):91-95.
Sandrini G, Franchini S, Lanfranchi S, et al. Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. Int J Clin Pharmacol Res 1998;18(3):145-150.
Wu GH, Zhang YW, Wu ZH. Modulation of postoperative immune and inflammatory response by immune-enhancing enteral diet in gastrointestinal cancer patients. World J Gastroenterol 2001;7(3): 357-362.
January 01, 2004

Thursday, June 23, 2005

Antineoplastons

Antineoplastons


Background


Antineoplastons are a group of naturally occurring peptide fractions which were observed by Stanislaw Burzynski, MD, PhD in the late 1970s to be absent in the urine of cancer patients. It was hypothesized that these substances may have anti-tumor properties. In the 1980s, Burzynski identified chemical structures for several of these antineoplastons, and developed a process to prepare them synthetically. Antineoplaston A10, identified as 3-phenylacetylamino-2,6-piperidinedione, was the first to be synthesized.

The use of antineoplastons in the treatment of various cancer types has been studied in the laboratory and in animals, and in limited preliminary human research. In 1991, the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) examined records of seven patients with brain tumors treated at the Burzynski Clinic in Texas. Based on their findings, the NCI sponsored a brain tumor clinical trial. However, due to difficulty recruiting patients, and a disagreement over study design, this research was canceled. The results in nine patients included prior to cancellation were reported, but were not conclusive. In 1997, Dr. Burzynski had legal troubles for permitting antineoplastons to be shipped out of Texas.

There is a lack of sufficient evidence from randomized, controlled trials in support of antineoplastons as a cancer treatment, and antineoplastons are not FDA approved therapies. Antineoplastons are not widely available in the United States, and safety and efficacy are not proven. Multiple studies of antineoplastons in various cancers have been sponsored by the Burzynski Research Institute. In recent years, antineoplastons have also been suggested to treat other conditions such as Parkinson's disease, sickle cell anemia, and thalassemia.

Synonyms


A1, A2, A3, A4, A5, A10, A10-1, AS2-1, AS2-5, AS5, Antineoplaston A, Antineoplaston H, Antineoplaston L, Antineoplaston O, Antineoplaston F, Antineoplaston Ch, Antineoplaston K, 3-N-phenylacetylaminopiperidine-2,6 dione, Phenylacetylglutamine (PAG), Phenylacetylisoglutamine (PAIG), Phenylacetic acid (PAA), 3-phenylacetylamino-2,6-piperidinedione, sodium phenylacetate.

Evidence

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Uses based on scientific evidenceGrade*Cancer
There is inconclusive scientific evidence regarding the effectiveness of antineoplastons in the treatment of cancer. Several preliminary human studies (case series, phase I/II trials) have examined antineoplaston types A2, A5, A10, AS2-1, and AS2-5 for a variety of cancer types. It remains unclear if antineoplastons are effective, or what doses may be safe. Until better research is available, no clear conclusion can be drawn.

C
HIV
A small preliminary study published by Dr. Burzynski and colleagues in 1992 reported increased energy and weight in patients with HIV, as well as a decreased number of opportunistic infections, and increased CD4+ counts overall. These patients were treated with antineoplaston AS2-1. However, this evidence cannot be considered conclusive. Currently, there are drug therapy regimens available for HIV with clearly demonstrated effects ("HAART" or "highly active anti-retroviral therapy), and patients with HIV are recommended to consult with a physician about treatment options.
C
Sickle cell anemia/thalassemia
A small preliminary study reported positive findings, but there is currently insufficient evidence to make a clear recommendation in this area.
C
* Key to grades
A: Strong scientific evidence for this use;
B: Good scientific evidence for this use;
C: Unclear scientific evidence for this use;
D: Fair scientific evidence against this use (it may not work);
F: Strong scientific evidence against this use (it likely does not work).


Uses based on tradition or theory
The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.

Acute lymphocytic leukemia, adenocarcinoma, aging, astrocytoma, basal cell epithelioma, bladder cancer, brain/central nervous system tumors, cholesterol/triglyceride abnormalities, chronic lymphocytic leukemia, colon cancer, encephalitis, glioblastoma, hepatocellular carcinoma, leukocytosis, malignant melanoma, medulloblastoma, metastatic synovial sarcoma, Parkinson's disease, promyelocytic leukemia, prostate cancer, rectal cancer, skin cancer, thrombocytosis.

Dosing

The below doses are based on scientific research, publications, traditional use, or expert opinion. Many herbs and supplements have not been thoroughly tested, and safety and effectiveness may not be proven. Brands may be made differently, with variable ingredients, even within the same brand. The below doses may not apply to all products. You should read product labels, and discuss doses with a qualified healthcare provider before starting therapy.

Adults (18 years and older)

Various doses of antineoplastons have been used in preliminary studies. Safety and effectiveness are not proven for any specific dose or use. Doses of antineoplaston A10 used by mouth in studies range from 10 to 40 grams daily or 100 to 288 milligrams per kilogram of body weight per day. Duration of use has varied. Antineoplaston AS2-1 has been studied at doses from 12 to 30 grams daily or 97 to 130 milligrams per kilogram of body weight per day. Antineoplastons have also been studied when applied to the skin, injected through the veins (intravenous) and injected into muscles (intramuscular).

Children (younger than 18 years)

There is insufficient available data to safely recommend the use of antineoplastons in children.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Allergies

Allergic skin rash has been reported after injection of antineoplaston AS2-1. Individuals who have reacted to antineoplastons in the past should avoid this therapy.

Side Effects and Warnings

Adverse effects are reported in several preliminary studies. It is not clear how common these reactions are, or if they occur more frequently than with placebo. Since many patients taking antineoplastons have been diagnosed with serious illnesses such as advanced cancers, it is not clear if these effects may be from the illnesses themselves, or caused by antineoplastons.

Antineoplaston therapy has been associated with drowsiness, headache, fatigue, mild dizziness/vertigo, and confusion. Antineoplaston A10 is retained in the brain tissue of animals, although the importance of this in humans is not known. Weakness, nausea, vomiting, upset stomach, abdominal pain, and increased flatulence (gas) have been reported.

Various types of antineoplastons administered from weeks to years have been associated with sore throat, fever, chills, reduced blood albumin levels, liver function test abnormalities, low blood sugar levels (hypoglycemia), low potassium, and a strong body odor similar to urine.

Palpitations, high blood pressure (hypertension), and mild peripheral edema (water retention) have been noted. Chest pressure and irregular or fast heart beat have also been observed. Joint swelling, muscle/joint pain, muscle contractions in the throat, weakness, and finger rigidity have been reported in clinical trials.

Decreases in blood platelets, red blood cells, and white blood cells have been observed. Other serious reported effects include slow or abnormal breathing, metabolic/electrolyte abnormalities, cerebral edema (brain swelling), dangerously low blood pressure (hypotension), and death.

Pregnancy and Breastfeeding

The safety of antineoplastons during pregnancy or breastfeeding is not known, and therefore cannot be recommended.

References

Badria F, Mabed M, El Awadi M, et al. Immune modulatory potentials of antineoplaston A-10 in breast cancer patients. Cancer Lett 2000;157(1):57-63.
Badria F, Mabed M, Khafagy W, et al. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett 2000;157(1):67-70.
Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145.
Burzynski R. Isolation, purification, and synthesis of antineoplastons. Int J Exper Clin Chemother 1989;2:63-69.
Burzynski R. Treatment of bladder cancer with antineoplaston formulations. Adv Exp Clin Chemother 1988;2:37-46.
Burzynski SR, Conde AB, Peters A, et al. Retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18:1-10.
Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplaston A10 and AS2-1 infusion in astrocytoma. In: Adam D, Buchner T, Rubinstein E, editors. Recent Advances in Chemotherapy. Munich: Futuramed Publishers, 1991:2506-2507.
Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990;16(7):361-369.
Burzynski SR, Kubove E, Szymkowski B, et al. Phase II clinical trials of novel differentiation inducer--antineoplaston AS2-1 in AIDS and asymptomatic HIV infection [abstract]. Int Conf AIDS 1992;8(3):61 (abstract no. PuB 7074).
Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995;7(3):157-167.
Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
Choi BG. Synthesis of antineoplaston A10 as potential antitumor agents. Arch Pharm Res 1998;21(2):157-163.
Green S. 'Antineoplastons' An unproved cancer therapy. JAMA 1992;267 (21) :2924-2928.
Juszkiewicz M, Chodkowska A, Burzynski SR, et al. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exp Clin Res 1995;21(4):153-156.
Kumabe T. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncology Rep 1998;5(6):1363-1367.
Liau MC, Szopa M, Burzynski B, et al. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exp Clin Res 1987;13 Suppl 1:61-70.
Soltysiak-Pawluczuk D, Burzynski SR. Cellular accumulation of antineoplaston AS21 in human hepatoma cells. Cancer Lett 1995;88(1):107-112.
Sugita Y, Tsuda H, Maruiwa H, et al. The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Kurume Med J 1995;42(3):133-140.
Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249.
Tsuda H, Iemura A, Sata M, et al. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J 1996;43(2):137-147.
Tsuda H, Sata M, Kumabe T, et al. Quick response of advanced cancer to chemoradiation therapy with antineoplastons. Oncology Rep 1998;5(3):597-600.
Tsuda H, Sata M, Saitsu H, et al. Antineoplaston AS2-1 for maintenance therapy in liver cancer. Oncol Rep 1997;4:1213-1216.
Tweddle S, James N. Lessons from antineoplaston. Lancet 1997;349(9054):741.
January 01, 2004